Objective: To explore the clinicopathological correlation between transcriptional activator factor 3 (ATF3) and overweight/obese patients with colorectal cancer (CRC) and its diagnostic efficacy, and to assess its value of being molecular marker for early diagnosis of CRC by detecting its expression levels in the serum of overweight/obese colorectal cancer patients and healthy physical examiners. Methods: The expression levels of ATF3 in the serum of 34 colorectal cancer patients and 24 healthy physical participants were detected using enzyme-linked immunosorbent assay (ELISA), and the relation＜between ATF3 expression levels and the clinicopathological features of CRC was analyzed. The diagnostic efficacy of ATF3 was assessed using ROC curves and compared with the commonly used carcinoembryonic antigen to evaluate its clinical value of being a molecular marker in the diagnosis of CRC in overweight/obese people. Results: There was no significant difference in the expression levels of serum ATF3 between normal weight CRC patients and healthy participants, and the expression levels of serum ATF3 in overweight/obese CRC patients were significantly higher than those in overweight/obese healthy participants (P＜0.05). The ROC curves showed that the diagnostic efficacy of ATF3 in overweight/obese CRC patients was higher than that of the commonly used carcinoembryonic antigen. Conclusion: The elevated expression level of ATF3 in the serum of overweight/obese CRC patients is closely related to the progression of colorectal cancer. ATF3 is potential to become a serological indicator for the molecular diagnosis of CRC in overweight/obese population.
LIU Xiuliang
,
LI Ruibin
,
WAN Zhiheng
. Clinical significance of ATF3 gene expression in the serum of overweight/obese patients with colorectal cancer[J]. Journal of Baotou Medical College, 2024
, 40(3)
: 16
-20
.
DOI: 10.16833/j.cnki.jbmc.2024.03.004
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Chen YX, Liu C, Zhu SM, et al. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: immunotherapeutic amplification strategies against colorectal cancer[J]. Int Immunopharmacol, 2021, 96: 107607.
[3] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480.
[4] Wang B, Yang X, Sun X, et al. ATF3 in atherosclerosis: a controversial transcription factor[J]. J Mol Med (Berl), 2022, 100(11): 1557-1568.
[5] Wu XW, Nguyen BC, Dziunycz P, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer[J]. Nature, 2010, 465(7296): 368-372.
[6] Ku HC, Cheng CF. Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer[J]. Front Endocrinol, 2020, 11: 556.
[7] Chen ML, Liu YJ, Yang YQ, et al. Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: implications in cancer immunotherapy[J]. Genes Dis, 2021, 9(4): 981-999.
[8] Kim S, Song NJ, Bahn G, et al. Atf3 induction is a therapeutic target for obesity and metabolic diseases[J]. Biochem Biophys Res Commun, 2018, 504(4): 903-908.
[9] Ku HC, Chan TY, Chung JF, et al. The ATF3 inducer protects against diet-induced obesity via suppressing adipocyte adipogenesis and promoting lipolysis and browning[J]. Biomed Pharmacother, 2022, 145: 112440.
[10] Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer[J]. Int J Mol Sci, 2022, 23(2): 852.
[11] Yan F, Ying L, Li XF, et al. Overexpression of the transcription factor ATF3 with a regulatory molecular signature associates with the pathogenic development of colorectal cancer[J]. Oncotarget, 2017, 8(29): 47020-47036.
[12] Hackl C, Lang SA, Moser C, et al. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition[J]. BMC Cancer, 2010, 10: 668.
[13] Wu ZY, Wei ZM, Sun SJ, et al. Activating transcription factor 3 promotes colon cancer metastasis[J]. Tumour Biol, 2014, 35(8): 8329-8334.
[14] Jang MK, Jung MH. ATF3 represses PPARγ expression and inhibits adipocyte differentiation[J]. Biochem Biophys Res Commun, 2014, 454(1): 58-64.
[15] Jang MK, Son Y, Jung MH. ATF3 plays a role in adipocyte hypoxia-mediated mitochondria dysfunction in obesity[J]. Biochem Biophys Res Commun, 2013, 431(3): 421-427.
[16] Zhu HJ, Liu MJ, Zhang NR, et al. Serum and adipose tissue mRNA levels of ATF3 and FNDC5/irisin in colorectal cancer patients with or without obesity[J]. Front Physiol, 2018, 9: 1125.
